Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment
Open accessThe DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Abstract
The tumor microenvironment (TME) in breast cancer comprises local factors, cancer cells, immune cells and stromal cells of the local and distant tissues. The interaction between cancer cells and their microenvironment plays important roles in tumor proliferation, propagation and response to therapies. There is increasing research in exploring and manipulating the non-cancerous components of the TME for breast cancer treatment. As the TME is now increasingly recognized as a treatment target, its pathologic assessment has become a critical component of breast cancer management. The latest WHO classification of tumors of the breast listed stromal response pattern/fibrotic focus as a prognostic factor and includes recommendations on the assessment of tumor infiltrating lymphocytes and PD-1/PD-L1 expression, with therapeutic implications. This review dissects the TME of breast cancer, describes pathologic assessment relevant for prognostication and treatment decision, and details therapeutic options that interacts with and/or exploits the TME in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–213 of 213
Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer
Kwon, M. J. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01189-y · Cited by 38
Lee, H., Lee, M., Seo, J.-H., Gong, G., & Lee, H. J. (2020) · Anticancer Research · doi:10.21873/anticanres.14142 · Cited by 38
Triulzi, T., Cecco, L. D., Sandri, M. F., Prat, A., Giussani, M., Paolini, B., Carcangiu, M. L., Canevari, S., Bottini, A., Balsari, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4405 · Cited by 37
Kochi, M., Iwamoto, T., Niikura, N., Bianchini, G., Masuda, S., Mizoo, T., Nogami, T., Shien, T., Motoki, T., Taira, N., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4502-3 · Cited by 36
Antitumor Antibodies Can Drive Therapeutic T Cell Responses
Wittrup, K. D. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.07.001 · Cited by 35 · cited 1×
“Their anti-tumor activities are mediated by the recognition of tumor-specific antigens and antibody production or antigen presenting cell (APC) function [23,24].”
BackgroundCytokine profile of breast cell lines after different radiation doses
Bravatà, V., Minafra, L., Forte, G. I., Cammarata, F. P., Russo, G. I., Maggio, F. M. D., Augello, G., Lio, D., & Gilardi, M. C. (2017) · International Journal of Radiation Biology · doi:10.1080/09553002.2017.1362504 · Cited by 33 · cited 4×
“In a mouse model of breast cancer, doxorubicin treatment led to recruitment of CCR2-expressing monocytic cells by stroma-derived CCL2, dampens treatment response and promotes tumor re-emergence [118].”
BackgroundInfluentialKim, A., Heo, S., Kim, Y., Gong, G., & Lee, H. J. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw097 · Cited by 31
Lim, K. H. J., Telisinghe, P. U., Abdullah, M. S., & Ramasamy, R. (2010) · PubMed · Cited by 30
Millar, E. K. A., Browne, L. H., Šlapetová, I., Shang, F., Ren, Y., Bradshaw, R., Brauer, H. A., O’Toole, S. A., Beretov, J., Whan, R. M., et al. (2020) · Cancers · doi:10.3390/cancers12092365 · Cited by 30
Chan, R., Li, J. J. X., Yeung, W. W., & Chan, A. W. H. (2020) · Diagnostic Cytopathology · doi:10.1002/dc.24344 · Cited by 23
Self-citationCao, Y., Dong, L., He, Y., Hu, X., Hou, Y., Dong, Y., Yang, Q., Bi, Y., & Liu, G. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30263 · Cited by 22 · cited 1×
“Follicular helper T-cells (Tfh) play important roles in antigen specific B-cell maturation, promoting local memory cell differentiation and supporting the development of tertiary lymphoid organ thus enhancing local anti-tumor immune response [18,19].”
BackgroundPark, M., Oh, E., Song, M.-J., Kim, W., Cho, Y. U., Kim, S. J., Han, J., Suh, J., Choi, E. K., Lim, B. U., et al. (2012) · Microvascular Research · doi:10.1016/j.mvr.2012.06.002 · Cited by 19
Kozlowski, H. N., & Hrabowska, M. (1975) · PubMed · Cited by 5
Metadata
- Authors
- Li, J. J., Tsang, J. Y., & Tse, G. M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-08-23
- Volume
- 13
- Issue
- 16
- Pages
- 4233
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3194062143
- Cited by
- 180
- References
- 213
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.